SAM Chun Dang Pharm삼천당제약
000250 · KOSDAQ · ₩000250 · 삼천당제약
₩187,600▼ ₩1,300 (0.69%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩232B | ₩211B | ₩193B | ₩177B | ₩167B |
| Cost of sales | ₩122B | ₩111B | ₩96B | ₩87B | ₩84B |
| Gross profit | ₩109B | ₩100B | ₩97B | ₩90B | ₩83B |
| Operating income | ₩8.5B | ₩2.6B | ₩9.6B | ₩12B | −₩15B |
| Net income | ₩12B | −₩5.1B | −₩4.2B | ₩8.8B | −₩10B |
| Net income to shareholders | ₩5.3B | −₩11B | −₩10B | ₩5.8B | −₩17B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩561B | ₩520B | ₩408B | ₩373B | ₩344B |
| Current assets | ₩242B | ₩243B | ₩164B | ₩158B | ₩169B |
| Cash and equivalents | ₩96B | ₩106B | ₩40B | ₩22B | ₩49B |
| Total liabilities | ₩198B | ₩170B | ₩110B | ₩128B | ₩94B |
| Current liabilities | ₩107B | ₩93B | ₩58B | ₩38B | ₩54B |
| Borrowings | ₩45B | ₩45B | ₩48B | ₩71B | ₩48B |
| Total equity | ₩364B | ₩349B | ₩298B | ₩246B | ₩250B |
| Shareholders' equity | ₩276B | ₩266B | ₩220B | ₩174B | ₩174B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩9.8B | ₩22B | ₩23B | ₩13B | −₩7.7B |
| Capital spending | ₩46B | ₩17B | ₩6.8B | ₩17B | ₩15B |
| Free cash flow | −₩36B | ₩4.7B | ₩17B | −₩3.3B | −₩23B |
| Dividends paid | ₩4.7B | ₩890M | ₩881M | ₩968M | ₩968M |
Consolidated where available. Amounts in won.
Also known as: SAM Chun Dang Pharm / 삼천당제약 / 000250 / KRX:000250
Source: KRX statistical information